Edwards Lifesciences (EW) Tops Q1 EPS by 10c; Raises Outlook

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $1.32, $0.10 better than the analyst estimate of $1.22. Revenue for the quarter came in at $993 million versus the consensus estimate of $989.61 million.

GUIDANCE:

Edwards Lifesciences sees FY2019 EPS of $5.10-$5.35, from $5.05 to $5.30 and versus the consensus of $5.21.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• TotalEnergies strikes $1.8B deal with GIP on African assets
• Intuit holds investor day, reaffirms fiscal 2027 guidance